Clinical Trial

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 2, 2026 (before its estimated April 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
Objective: To explore the curative effect and safty of Changchun Ruibin metronomic chemotherapy combined with endistat in the treatment of HR positive HER2 negative advanced breast carcinoma.
Trial Details
NCT Number NCT07441486
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Breast Cancer
Enrollment 50 participants
Start Date 2026-04-01
Primary Completion 2026-04-10 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-02